DRL_RI is being developed as a biosimilar of rituximab, a cluster of differentiation 20 directed cytolytic antibody for approval in the United States, European Union and other regions for various indications including treatment of adult patients with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis.
Dr. Reddy's rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets.
The company undertook further clinical development to meet regulatory requirements of highly regulated markets.
With the successful completion of these clinical studies, Dr. Reddy's is now preparing to file Biologics License Application / Marketing Authorisation Application dossiers with various regulatory authorities globally.
Dr. Reddy's is currently collaborating with its partner Fresenius Kabi to commercialise its proposed biosimilar of rituximab in the United States.
The company intends to commercialise the product in Europe and other geographies directly.
Dr. Reddy's biosimilars business is part of its key strategic initiatives expected to drive both near-term and future growth.
Over the last 20 years, the company's Biologics team has developed into a fully integrated organisation with robust capabilities in the development, manufacture and commercialisation of a range of biosimilar products in oncology and immunology.
BenevolentAI and AstraZeneca collaboration leads to novel target for lupus
UCB announces results from three studies supporting the value of CIMZIA(R) (certolizumab pegol)
Henlius and Organon report success of HLX14 Phase 3 study
Nobelpharma's inhaled use of Leukine receives Japanese regulatory approval to treat aPAP
RemeGen's Telitacicept receives US FDA Fast Track Designation
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
AstraZeneca announces US approval for Ultomiris for NMOSD treatment
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis